Synonym
AA 193; AA-193; AA193
IUPAC/Chemical Name
Furo(2,3-g)-1,2-benzisoxazole-7-carboxylic acid, 5-chloro-7,8-dihydro-3-phenyl-
InChi Key
RVKIPRIYUGLRFF-UHFFFAOYSA-N
InChi Code
InChI=1S/C16H10ClNO4/c17-11-6-9-13(8-4-2-1-3-5-8)18-22-14(9)10-7-12(16(19)20)21-15(10)11/h1-6,12H,7H2,(H,19,20)
SMILES Code
O=C(C(O1)CC2=C1C(Cl)=CC3=C2ON=C3C4=CC=CC=C4)O
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>2 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
Preparing Stock Solutions
The following data is based on the
product
molecular weight
315.71
Batch specific molecular weights may vary
from batch to batch
due to the degree of hydration, which will
affect the solvent
volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass |
1 mg |
5 mg |
10 mg |
| 1 mM |
1.15 mL |
5.76 mL |
11.51 mL |
| 5 mM |
0.23 mL |
1.15 mL |
2.3 mL |
| 10 mM |
0.12 mL |
0.58 mL |
1.15 mL |
| 50 mM |
0.02 mL |
0.12 mL |
0.23 mL |
1: Yamada H, Kotaki H, Furitsu H, Sawada Y, Iga T. Mechanism of the uricosuric action of E3040, a drug used to treat inflammatory bowel disease II: study using DBA/2N mice. Biopharm Drug Dispos. 1999 Jul;20(5):271-6. PubMed PMID: 10594872.
2: Yamada H, Kotaki H, Itoh T, Sawada Y, Iga T. Effect of anti-inflammatory bowel disease drug, E3040, on urate transport in rat renal brush border membrane vesicles. Eur J Pharmacol. 2000 Oct 6;406(1):45-8. PubMed PMID: 11011031.
3: Lim RW, Furukawa R, Fechheimer M. Evidence of intramolecular regulation of the Dictyostelium discoideum 34 000 Da F-actin-bundling protein. Biochemistry. 1999 Dec 7;38(49):16323-32. PubMed PMID: 10587457.
4: Dan T, Onuma E, Tanaka H, Koga H. A selective uricosuric action of AA-193 in rats. Comparison with its effect on PAH secretion in vivo and in vitro. Naunyn Schmiedebergs Arch Pharmacol. 1991 May;343(5):532-7. PubMed PMID: 1881462.
5: Dan T, Koga H, Onuma E, Tanaka H, Sato H, Aoki B. The activity of AA-193, a new uricosuric agent, in animals. Adv Exp Med Biol. 1989;253A:301-8. PubMed PMID: 2624207.
6: Dan T, Yoneya T, Onoma M, Onuma E, Ozawa K. Hypouricemic and uricosuric actions of AA-193 in a hyperuricemic rat model. Metabolism. 1994 Jan;43(1):123-8. PubMed PMID: 8289669.
7: Dan T, Tanaka H, Koga H. Mechanism of uricosuric action of AA-193 in DBA/2N mice. J Pharmacol Exp Ther. 1990 May;253(2):437-43. PubMed PMID: 2338641.
8: Dan T, Koga H. Uricosurics inhibit urate transporter in rat renal brush border membrane vesicles. Eur J Pharmacol. 1990 Oct 23;187(3):303-12. PubMed PMID: 2073918.
9: Kurane I, West K, Tuazon CU, Zeng W, Ennis FA. Definition of two new epitopes on human immunodeficiency virus type 1 gag protein recognized by human CD8+ cytotoxic T lymphocyte clones. J Clin Virol. 2003 May;27(1):38-43. PubMed PMID: 12727527.
10: Sato H, Dan T, Onuma E, Tanaka H, Aoki B, Koga H. Studies on uricosuric diuretics. II. Substituted 7,8-dihydrofuro[2,3-g]-1,2-benzisoxazole-7-carboxylic acids and 7,8-dihydrofuro[2,3-g]benzoxazole-7-carboxylic acids. Chem Pharm Bull (Tokyo). 1991 Jul;39(7):1760-72. PubMed PMID: 1777929. H
